Overview

* United Therapeutics ( UTHR ) Q3 revenue grows 7% yr/yr but misses analyst expectations

* Net income for Q3 rises 10% yr/yr to $338.7 mln

* Company repurchased $1 bln of common stock in Q3

Outlook

* United Therapeutics ( UTHR ) did not provide specific financial guidance for future periods

Result Drivers

* TYVASO DPI GROWTH - Increased quantities sold and price rise drove 22% revenue growth for Tyvaso DPI

* ORENITRAM SALES - Orenitram revenues increased 16% due to higher quantities sold and price increase

* TETON-2 STUDY IMPACT - Breakthrough TETON-2 study results in idiopathic pulmonary fibrosis could broaden therapeutic reach

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $799.50 $817 mln

Revenue mln (10

Analysts

)

Q3 EPS $7.16

Q3 Net $338.70

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for United Therapeutics Corp ( UTHR ) is $500.00, about 16.9% above its October 28 closing price of $415.34

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)